openPR Logo
Press release

Companion Diagnostic Tests in Oncology Market Research Report Forecast to 2024

09-29-2017 12:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Companion Diagnostic Tests in Oncology Market

Companion Diagnostic Tests in Oncology Market

“The global market for companion diagnostic tests in oncology is anticipated to rise at an outstanding 16.8% CAGR from 2017 to 2025. Rising from a valuation of US$3.5 bn in 2016, the market is likely to touch US$13.6 bn by 2025.” The application of companion diagnostic tests in oncology will be largely in detecting breast cancer. This is anticipated to provide the much needed push to the segment of breast cancer over the years ahead. It is expected to thus exhibit a 17.0% CAGR over the course of the forecast period. Region-wise, the global market for companion diagnostic tests in oncology is likely to be dominated by North America with an approximate share of 37.5% by 2025. The high acceptance rate of novel technologies in the region is one of the core reasons behind the dominance of North America on the regional front.

The developing need for personalized healthcare alongside targeted treatments have expanded the development of the worldwide companion diagnostic tests in oncology market. The pharmaceutical industry is step by step advancing toward creating particular treatments to treat various sorts of chronic diseases such as cancer. The take-up of companion diagnostic tests and biomarkers have empowered human services suppliers to offer a scope of appropriate treatments to the patients, in this manner guaranteeing quicker recuperating time. High pervasiveness of malignancy, expanding danger of growth, way of life changes, and regular event of ailments, for instance, Hepatitis are relied upon to drive the worldwide market.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4684

The worldwide market for companion diagnostic tests in oncology is likewise profiting by the remarkable diminishment in the cost of drug discovery because of selection of companion diagnostics. These diagnostics are utilized as a part of the procedure of drug discovery as they diminish the time spent in clinical trials by conveyance quicker outcomes in a proficient and successful way. This factor is surveyed to assume an instrumental part in characterizing the direction of the worldwide market for companion diagnostic tests in oncology. The developing concerns about neglected restorative needs are additionally anticipated to boost the demand for companion diagnostic tests in oncology in the coming years as pharmaceutical organizations will concentrate on innovative work to present new medications.

The postponed procedures of endorsements for targeted therapies are relied upon to hamper the development of the worldwide companion diagnostic tests in oncology. Moreover, the inconvenience repayment situation has likewise discouraged the worldwide market in the course of recent years. The scattered interest of partners in the worldwide market is likewise going about as an obstruction to the growth of the market.

Request to Download TOC of the Report: http://www.transparencymarketresearch.com/report-toc/4684

The degree of competition in the global companion diagnostic tests in oncology market for is likely to range from moderate to high owing to the fact that numerous manufacturers are looking forward to collaborate with several pharmaceutical manufacturers, states Transparency Market Research (TMR) in a research report. Moreover, the rising number of vendors in the market with several cutting edge technologies is also anticipated to put the position of established players at stake in the years ahead. The leading three players namely Agilent Technologies Inc., Abbott Laboratories, and Illumina Inc., accounted for a share of 23% in the global market for companion diagnostics tests in oncology in 2016. These vendors are also anticipated to concentrate on partnerships and product innovation to stay competitive in the market in the years ahead.

Global Companion Diagnostic Tests in Oncology Market Report is available @ US$ 5795 : http://www.transparencymarketresearch.com/checkout.php?rep_id=4684<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Companion Diagnostic Tests in Oncology Market Research Report Forecast to 2024 here

News-ID: 748385 • Views: 87

More Releases from Transparency Market Research

Distributed Operating System Market: A Latest Research Report to Share Industry …
A distributed operating system is a software which is a collection of distinct computational nodes that are networked, independent, and communicating in order to perform certain operations The distributed operating system manages the jobs that are serviced by multiple processing units. Every distinct node holds a precise software subset of the global collective operating system. Each subset is a composite of two distinct service provisions. The first subset is a universal kernel,
Research Outlines Huge Growth In Automatic Dependent Surveillance Broadcast Mark …
Automatic dependent surveillance-broadcast (ADS-B) is surveillance technology which enables an aircraft to determine its position through satellite navigation. Automatic dependent surveillance-broadcast (ADS-B) helps to track an aircraft through periodical broadcasts. As a replacement for secondary surveillance radar, automatic dependent surveillance - broadcast (ADS–B) technology can be used by air traffic control ground stations to gather information regarding tracking of the aircraft. It can also be used by other aircrafts to enable
RF Shielded Test Enclosures Market: Structure and Overview of Key Industry
RF shielded test enclosures, also called RF shielded test boxes, are used for testing of RF and microwave devices in an isolated test environment, which lacks interference of other devices as well as the external environment These test boxes are used in isolation from unintended electromagnetic interference in noisy surroundings. In order to check whether a device is functioning up to the mark in an isolated environment, these boxes are used
Pitot Tube Anemometers Market Will Escalate Rapidly in the Near Future
A pitot tube anemometer is a flow measurement device that is designed to measure and display air pressure, air velocity, volumetric flow, and air temperature Pitot tube anemometers involve use of the microprocessor technology for signal processing, which ensures quick and accurate measuring results Pitot tube anemometers are available in two types i.e. portable and fixed When not in use, a pitot tube anemometer should be placed in dry conditions and be protected

All 5 Releases


More Releases for Companion

Companion Diagnostics Market – Growth , Opportunities and Applications
Companion diagnostics are tests to understand which patient can be benefited from a certain drug or what dosage should be prescribed based upon patient’s clinical diagnosis, which provides evidence required for the successful and harmless use of an equivalent drug or biological product to treat the medical condition. These are medical instruments that support doctors to elect which treatment and dosage should be given to patients personalized to their necessity. Companion
A Smart Companion to your TV
Following HELLO’s very successful Kickstarter campaign (1339% funded), Solaborate is launching the new and improved HELLO 2 on Kickstarter, along with HELLO Touch TV, HELLO Creator Edition and 2 Gadget Extensions. A Smart Companion to your TV HELLO 2, like its predecessor, turns any TV into a video communication and collaboration device. HELLO 2 does everything users love about the original even better with Alexa support, home automation (Zigbee), and Android games,
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Farm & Companion Animal Health Market
Veterinary healthcare products include pharmaceuticals, nutrition (feed additives) and devices for both companion and livestock animals. Companion animals include pets such as dogs, cats and horses; although in recent years the market has expanded reasonably for avian pets, reptiles and exotic fish. The healthcare products have transformed the health and quality of life for millions of pets across the world. The greatest challenge of maintaining pets is seeking the keenness
Global Companion Diagnostics Market to Grow Globally
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.